Skip NavigationSkip to Content
Return Return to Search Results

Clinical evaluation of commercial SARS-CoV-2 serological assays in a malaria endemic setting

  1. Author:
    Dabitao, Djeneba
    Shaw-Saliba, Kathryn
    Konate, Drissa S
    Highbarger,Helene
    Lallemand,Perrine
    Sanogo, Ibrahim
    Rehman,Tauseef
    Wague, Mamadou
    Coulibaly, Nadie
    Kone, Bourahima
    Baya, Bocar
    Diakite, Seidina A S
    Samake, Seydou
    Akpa, Esther
    Tounkara, Moctar
    Laverdure, Sylvain
    Doumbia, Seydou
    Lane, H Clifford
    Diakite, Mahamadou
    Dewar,Robin

  2. Author Address

    University Clinical Research Center (UCRC), Faculty of Pharmacy and Faculty of Medicine and Odonto-Stomatology, University of Sciences, Techniques, and Technologies of Bamako (USTTB), West Africa, Mali. Electronic address: ddabitao@icermali.org., Collaborative Clinical Research Branch (CCRB), Division of Clinical Research (DCR), National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, USA., Virus Isolation and Serology Laboratory, Frederick National Laboratory (FNL)., Laboratory of Human Retrovirology and Immunoinformatics, Frederick National Laboratory (FNL).,
    1. Year: 2023
    2. Date: May 11
    3. Epub Date: 2023 05 11
  2. Journal: Journal of Immunological Methods
    1. Pages: 113488
  4. Type of Article: Article
  5. Article Number: 113488
  1. Abstract:

    The levels of immune response to SARS-CoV-2 infection or vaccination are poorly understood in African populations and is complicated by cross-reactivity to endemic pathogens as well as differences in host responsiveness. To begin to determine the best approach to minimize false positive antibody levels to SARS-CoV-2 in an African population, we evaluated three commercial assays, namely Bio-Rad Platelia SARS-CoV-2 Total Antibody (Platelia), Quanterix Simoa Semi-Quantitative SARS-CoV-2 IgG Antibody Test (anti-Spike), and the GenScript cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit (cPass) using samples collected in Mali in West Africa prior to the emergence of SARS-CoV-2. A total of one hundred samples were assayed. The samples were categorized in two groups based on the presence or absence of clinical malaria. Overall, thirteen out of one hundred (13/100) samples were false positives with the Bio-Rad Platelia assay and one of the same one hundred (1/100) was a false positive with the anti-Spike IgG Quanterix assay. None of the samples tested with the GenScript cPass assay were positive. False positives were more common in the clinical malaria group, 10/50 (20%) vs. the non-malaria group 3/50 (6%); p = 0.0374 using the Bio-Rad Platelia assay. Association between false positive results and parasitemia by Bio-Rad remained evident, after adjusting for age and sex in multivariate analyses. In summary, the impact of clinical malaria on assay performance appears to depend on the assay and/or antigen being used. A careful evaluation of any given assay in the local context is a prerequisite for reliable serological assessment of anti-SARS-CoV-2 humoral immunity. Copyright © 2023. Published by Elsevier B.V.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1016/j.jim.2023.113488
  3. PMID: 37179012
  4. PMCID: PMC10174340
  5. PII : S0022-1759(23)00070-4

Library Notes

  1. Fiscal Year: FY2022-2023
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel